KPG-818 is under clinical development by Kangpu Biopharmaceuticals and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KPG-818’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KPG-818 overview
KPG-818 is under development for the treatment of systemic lupus erythematosus, relapsed or refractory multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, indolent lymphoma, adult T-cell leukemia, T-cell lymphoma (ATL), or chronic lymphocytic leukemia (CLL), coronavirus disease 2019 (COVID-19) and Crohn's disease. It is administered by oral route formulated as capsule. It is an E3 ubiquitin ligase complex CRL4 modulator. It is being developed based on targeted protein degradation technology.
Kangpu Biopharmaceuticals overview
Kangpu Biopharmaceuticals (Kangpu) focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematological malignancies, auto-immune diseases that developed X-Synergy, a proprietary drug combination technology. Kangpu is headquartered in Shanghai, China.
For a complete picture of KPG-818’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
